DE69622386T2 - Synergistische kombinationen von zidovudine, 1592u89 und 3tc - Google Patents

Synergistische kombinationen von zidovudine, 1592u89 und 3tc

Info

Publication number
DE69622386T2
DE69622386T2 DE69622386T DE69622386T DE69622386T2 DE 69622386 T2 DE69622386 T2 DE 69622386T2 DE 69622386 T DE69622386 T DE 69622386T DE 69622386 T DE69622386 T DE 69622386T DE 69622386 T2 DE69622386 T2 DE 69622386T2
Authority
DE
Germany
Prior art keywords
zidovudine
synergistic combinations
synergistic
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69622386T
Other languages
English (en)
Other versions
DE122005000029I2 (de
DE69622386D1 (de
Inventor
Walter Barry
Clair Heider St
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69622386(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69622386D1 publication Critical patent/DE69622386D1/de
Publication of DE69622386T2 publication Critical patent/DE69622386T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69622386T 1995-03-30 1996-03-28 Synergistische kombinationen von zidovudine, 1592u89 und 3tc Expired - Lifetime DE69622386T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
DE69622386D1 DE69622386D1 (de) 2002-08-22
DE69622386T2 true DE69622386T2 (de) 2003-02-13

Family

ID=26306774

Family Applications (3)

Application Number Title Priority Date Filing Date
DE200512000029 Pending DE122005000029I1 (de) 1995-03-30 1996-03-28 Synergistische Kombinationen von Zidovudine, 1592u89 und 3tc.
DE1996622386 Active DE122005000029I2 (de) 1995-03-30 1996-03-28 Synergistische kombinationen von Zidovudine, 1592u89 und 3TC
DE69622386T Expired - Lifetime DE69622386T2 (de) 1995-03-30 1996-03-28 Synergistische kombinationen von zidovudine, 1592u89 und 3tc

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE200512000029 Pending DE122005000029I1 (de) 1995-03-30 1996-03-28 Synergistische Kombinationen von Zidovudine, 1592u89 und 3tc.
DE1996622386 Active DE122005000029I2 (de) 1995-03-30 1996-03-28 Synergistische kombinationen von Zidovudine, 1592u89 und 3TC

Country Status (36)

Country Link
US (1) US6417191B1 (de)
EP (1) EP0817637B1 (de)
JP (1) JP2954357B2 (de)
KR (1) KR100542536B1 (de)
CN (1) CN1103593C (de)
AP (1) AP652A (de)
AT (1) ATE220551T1 (de)
AU (1) AU715213B2 (de)
BR (3) BR9607851B1 (de)
CA (1) CA2216634C (de)
CZ (1) CZ295940B6 (de)
DE (3) DE122005000029I1 (de)
DK (1) DK0817637T3 (de)
EA (1) EA000626B3 (de)
EE (1) EE04047B1 (de)
ES (1) ES2179193T3 (de)
FR (1) FR05C0022I2 (de)
GE (1) GEP20022647B (de)
HK (1) HK1009401A1 (de)
HU (1) HU224010B1 (de)
IL (1) IL117727A (de)
LU (1) LU91171I2 (de)
MX (1) MX9707316A (de)
MY (1) MY115461A (de)
NL (1) NL300195I2 (de)
NO (2) NO313787B1 (de)
NZ (1) NZ306419A (de)
OA (1) OA10616A (de)
PL (1) PL187085B1 (de)
PT (1) PT817637E (de)
RO (1) RO117995B1 (de)
SI (1) SI0817637T1 (de)
SK (1) SK283825B6 (de)
TR (1) TR199701074T1 (de)
UA (1) UA60293C2 (de)
WO (1) WO1996030025A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ429498A3 (cs) * 1996-06-25 1999-06-16 Glaxo Group Limited Kombinace obsahující VX478, zidovudin, FTC a/nebo 3TC pro léčbu infekce HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
WO1998052570A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CA2512319A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
JP5415957B2 (ja) 2006-12-13 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
EP2982978A1 (de) 2009-05-27 2016-02-10 Immunaid Pty Ltd Verfahren zur behandlung von krankheiten
EP3351249A1 (de) 2010-01-27 2018-07-25 VIIV Healthcare Company Antivirale therapie
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
AU2015245217A1 (en) 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A2 (de) * 2017-08-29 2024-01-17 PureTech LYT, Inc. An das lymphatische system gerichtete lipidprodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
EP0513917B2 (de) * 1991-05-16 2001-03-07 Glaxo Group Limited Nukleosidanalogen enthaltende Antiviren-Zubereitungen
DK0639971T3 (da) * 1992-05-13 2000-03-20 Wellcome Found Terapeutiske kombinationer
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE230267T1 (de) 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
CZ429498A3 (cs) 1996-06-25 1999-06-16 Glaxo Group Limited Kombinace obsahující VX478, zidovudin, FTC a/nebo 3TC pro léčbu infekce HIV
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
AU715213B2 (en) 2000-01-20
EE04047B1 (et) 2003-06-16
NO974510L (no) 1997-09-29
AU5497296A (en) 1996-10-16
BR9607851A (pt) 1998-07-21
IL117727A0 (en) 1996-07-23
BR9607851B1 (pt) 2009-01-13
CN1185110A (zh) 1998-06-17
LU91171I9 (de) 2018-12-28
IL117727A (en) 1999-11-30
NL300195I2 (nl) 2005-11-01
CN1103593C (zh) 2003-03-26
BRPI9607851B8 (pt) 2019-11-05
DE122005000029I2 (de) 2006-04-27
CA2216634C (en) 2004-07-20
PL322532A1 (en) 1998-02-02
FR05C0022I1 (de) 2005-06-10
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
BRPI9612992B1 (pt) 2020-08-04
CZ295940B6 (cs) 2005-12-14
EA000626B1 (ru) 1999-12-29
CA2216634A1 (en) 1996-10-03
LU91171I2 (fr) 2005-07-04
NO313787B1 (no) 2002-12-02
NO2005014I2 (no) 2008-02-11
EA199700203A1 (ru) 1998-02-26
US6417191B1 (en) 2002-07-09
EP0817637B1 (de) 2002-07-17
KR100542536B1 (ko) 2006-03-23
DE122005000029I1 (de) 2005-10-06
RO117995B1 (ro) 2002-12-30
SK129597A3 (en) 1998-07-08
EA000626B3 (ru) 2016-04-29
MX9707316A (es) 1997-11-29
DE69622386D1 (de) 2002-08-22
NO2005014I1 (no) 2005-06-06
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
HK1009401A1 (en) 1999-09-10
JPH10511682A (ja) 1998-11-10
EP0817637A1 (de) 1998-01-14
FR05C0022I2 (de) 2005-10-21
EE9700240A (et) 1998-04-15
HUP9801571A2 (hu) 1999-01-28
HUP9801571A3 (en) 2001-04-28
SI0817637T1 (en) 2002-10-31
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
UA60293C2 (uk) 2003-10-15
HU224010B1 (hu) 2005-04-28
NO974510D0 (no) 1997-09-29
AP652A (en) 1998-06-19
DK0817637T3 (da) 2002-11-11
PL187085B1 (pl) 2004-05-31
ES2179193T3 (es) 2003-01-16
KR19980703420A (ko) 1998-11-05
ATE220551T1 (de) 2002-08-15
CZ309097A3 (cs) 1998-05-13
JP2954357B2 (ja) 1999-09-27
OA10616A (en) 2001-03-15
MY115461A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
ATE220551T1 (de) Synergistische kombinationen von zidovudine, 1592u89 und 3tc
DE69415157D1 (de) Elektrochirurgischer prozessor und anwendung
DE69627513D1 (de) Kochgerät und dessen betriebsverfahren
BR9702553A (pt) Composição cosmética e utilização
DE69608973T2 (de) Schalter und diesen enthaltende Schaltungsanordnung
DE69842004D1 (de) Substituierte 2-aminoacetamide und anwendung davon
DE69607321D1 (de) Reinigungsverfahren und zusammensetzung
DE69600316T2 (de) Haarkosmetische Zusammensetzung
BR9609831A (pt) Composições cosméticas e/ou farmacêuticas antipruríticas
ATE257708T1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
DE69624042T2 (de) TiO2 dotiertes, Ta2O5 enthaltendes dielektrisches Material und dieses enthaltende Bauteile
BR9611179A (pt) Composiç o em creme
BR9800753B1 (pt) composição cosmética e/ou dermatológica e uso de uma composição.
ATE228575T1 (de) Wirkstoffkombinationen
KR960030598U (ko) 이,미용원용가습장치
DE29512759U1 (de) Sitzanordnung von Belustigungsvorrichtungen
DE59607418D1 (de) Haarbehandlungsmittel
FI963720A0 (fi) N-aryyli- ja N-alkyylisulfonyyliaminaalit tuholaisten torjunta-aineina
PT101949A (pt) Boneco com elevacao simultania de bracos, pernas e abertura de olhos
FR2761061B1 (fr) Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
KR970028220U (ko) 판박이식 매니큐어
FI972988A0 (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
KR970020478U (ko) 마늘 세절기
ITRM950305A0 (it) Composizione cosmetica ad azione dermoprotettiva e dermonutritiva.

Legal Events

Date Code Title Description
R008 Case pending at federal patent court

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R039 Revocation action filed

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R431 Request for term correction

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R040 Withdrawal/refusal of revocation action now final

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222

R432 Decision on term correction now final

Free format text: PRODUCT NAME: ABACAVIR ODER EIN PHYSIOLOGISCH FUNKTIONALES DERIVAT DAVON IN KOMBINATION MIT LAMIVUDINE ODER EINEM PHYSIOLOGISCH FUNKTIONALEN DERIVAT DAVON; REGISTRATION NO/DATE: EU/1/04/298/001-002 20041217

Spc suppl protection certif: 122005000029

Filing date: 20050513

Expiry date: 20160329

Extension date: 20191222